Revised full-year figures to: net sales of 63,200 million yen, operating income 2,600 million yen, ordinary income 2,400 million yen, net income attributable to owners of the parent 1,950 million yen. Despite a year-on-year decline in sales by 3,800 million yen from the previous forecast, profits are raised. Under the mid-term plan, the promotion of the New Value Creation 1K Project aims to maintain solid profitability across core businesses.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"2929","jir_company_name":"PharmaFoods Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-09-09","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/09\/2929-20260909-01.pdf","jir_short_summary":"Revised full-year figures to: net sales of 63,200 million yen, operating income 2,600 million yen, ordinary income 2,400 million yen, net income attributable to owners of the parent 1,950 million yen. Despite a year-on-year decline in sales by 3,800 million yen from the previous forecast, profits are raised. Under the mid-term plan, the promotion of the New Value Creation 1K Project aims to maintain solid profitability across core businesses.","jir_summary":"### Key points of the news\nBased on the mid-term management plan, New Value Creation 1K Project, we will promote innovation in the healthcare sector and development of high-value-added products. We revise the full-year forecast for this term; sales are expected to be below the previous forecast, but profit items are raised, shifting management to prioritize financial soundness and capital efficiency.\n\n### Outlook and impact on investors\nProfitability improvements are pursued across each business, including pharma-gaba in the BtoB domain with expanding recruitment, BtoC products including New Value Creation 1K Project series, and broader industrial applications of Oboveur. Collaborative development with National Center for Global Health and Medicine indicates research and development activity. The plan is to continue expanding sales scale while prioritizing higher profitability and capital efficiency.","jir_financial_highlights":"Net sales: 63,200 (Compared with the previous forecast:\u25b23,800)\nOperating income: 2,600 (Compared with the previous forecast:\uff0b600)\nOrdinary income: 2,400 (Compared with the previous forecast:\uff0b400)\nNet income attributable to owners of the parent: 1,950 (Compared with the previous forecast:\uff0b450)\nEarnings per share: 67.14 (Compared with the previous forecast: unknown)","jir_category":"","jir_hashtags":"#PharmaFoods, #FullYearEarningsRevision, #NewValueCreation1KProject","jir_key_figures":"63,200: Net sales (million yen)\n2,600: Operating income (million yen)\n2,400: Ordinary income (million yen)","jir_meta_title":"PharmaFoods: Full-Year Earnings Revision | 63,200 million yen Net Sales, 2,600 million yen Operating Income, etc. for FY Ending July 2026","jir_meta_description":"PharmaFoods revises its full-year forecast for the FY ending July 2026. Net sales to 63,200 million yen, operating income to 2,600 million yen, net income 1,950 million yen. Strengthening the business shift and profitability-focused management under the mid-term plan New Value Creation 1K Project.","jir_og_title":"PharmaFoods | Notice of Full-Year Earnings Revision (FY2026 July)","jir_og_description":"PharmaFoods upwardly revises its full-year earnings forecast for the FY ending July 2026, with profits expected to exceed the previous year\u2019s results. Promoting business foundation and the New Value Creation 1K Project.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57923,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-111647","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n